EUbOPEN: A Partnership to Unlock Biology by 2035
Author Information
Author(s): Claudia Tredup, Suzanne Ackloo, Hartmut Beck, Peter J. Brown, Alex N. Bullock, Alessio Ciulli, Ivan Dikic, Kristina Edfeldt, Aled M. Edwards, Jonathan M. Elkins, Henner F. Farin, Edward A. Fon, Matthias Gstaiger, Judith Günther, Anna-Lena Gustavsson, Sandra Häberle, Laura Isigkeit, Kilian V. M. Huber, Andras Kotschy, Oliver Krämer, Andrew R. Leach, Brian D. Marsden, Hisanori Matsui, Daniel Merk, Florian Montel, Monique P. C. Mulder, Susanne Müller, Dafydd R. Owen, Ewgenij Proschak, Sandra Röhm, Alexandra Stolz, Michael Sundström, Frank von Delft, Timothy M. Willson, Cheryl H. Arrowsmith, Stefan Knapp
Hypothesis
How can a public-private partnership enhance the discovery of chemical probes for human proteins?
Conclusion
The EUbOPEN project aims to create and distribute a large set of high-quality chemical probes to aid in drug discovery for human proteins.
Supporting Evidence
- EUbOPEN aims to deliver 50 new chemical probes within a 5-year program.
- The project has established patient-derived assays to study disease mechanisms.
- EUbOPEN has distributed over 6000 samples of chemical probes to researchers worldwide.
- The initiative focuses on novel target classes, including E3 ligases and solute carriers.
- Data from the project will be made available in public repositories like ChEMBL.
Takeaway
EUbOPEN is a big team effort to find new medicines by making tools that help scientists study human proteins better.
Methodology
The project focuses on chemogenomic library collections, chemical probe discovery, profiling of compounds in patient-derived assays, and data sharing.
Limitations
The project faces challenges in developing selective chemical probes for a wide range of targets.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website